IQVのチャート
IQVの企業情報
| symbol | IQV |
|---|---|
| 会社名 | IQVIA Holdings Inc （IQV IQVIAホ―ルディングス） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 IQVIA・ホルディングス(IQVIA Holdings Inc.)（旧名：Quintiles IMS Holdings Inc.）は統合情報と技術対応の医療サービスを提供する。同社は3つの事業セグメントを運営する。商業ソリューション事業は国家と地方情報、技術ソリューション、ワークフロー分析とコンサルティングサービスを提供する。研究・開発ソリューション事業はバイオ医薬品開発サービスを提供する。同事業はプロジェクト管理、臨床モニタリング、臨床試験サポートサービス、クインタイルズとクエスト（Q2）ソリューション及び戦略的計画・設計等を提供する。統合エンゲージメント・サービス事業は医療供給者エンゲージメントサービス、患者エンゲージメントサービス及び科学戦略、医療業務サービスを提供する。同社の事業は米州、欧州とアフリカ、及びアジア太平洋地域に展開される。 IQVIAホ―ルディングスは米国のライフサイエンス企業。ヘルスケア産業を対象に医療・ヘルスケア情報およびサイエンスによるテクノロジ―ソリュ―ションを提供する。主にバイオ医薬品企業に対し臨床研究および臨床試験サ―ビスを提供するほか、ヘルスケア企業のマ―ケティング・販売戦略支援や、マネジメントコンサルティングを行う。 IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility - enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 70,000 employees, IQVIA conducts operations in more than 100 countries. |
| 本社所在地 | 919 998-2000 |
| 代表者氏名 | Ari Bousbib |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer |
| 電話番号 | +1 919-998-2000 |
| 設立年月日 | 1982年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 58000人 |
| url | www.quintiles.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 1950.00000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 28453.43000 |
| 売上高 | 売上高（百万ドル） 10412.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 38522.43000 |
| 当期純利益 | 当期純利益（百万ドル） 224.00000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Iqvia Holdings Inc revenues increased 7% to $10.41B. Net income before extraordinary items decreased 28% to $224M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Other segment loss increase of 13% to $1.14B Contract Sales_Medical Solutions segment income decrease of 20% to $59M. |
IQVのテクニカル分析
IQVのニュース
IQVIA Holdings – Consensus Indicates Potential 46.1% Upside 2022/09/29 10:43:29 DirectorsTalk
IQVIA Holdings found using ticker (IQV) have now 19 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 300 and 235 calculating the average target price we see 267.16. Now with the previous closing price of 182.89 this now indicates there is a potential upside of 46.1%. The 50 day MA is 221.32 while the 200 day moving average is 228.18. The market capitalisation for the company is $34,633m. You can visit the company''s website by visiting: https://www.iqvia.com [stock_market_widget type="chart" template="basic" color="green" assets="IQV" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $50,590m based on the market concensus. IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
IQVIA announces partnership with Dr Reddy''s Laboratories for CRM Solution for India Field Force 2022/09/28 10:05:03 Business Standard
Mumbai (Maharashtra)/Bangalore (Karnataka) [India], September 28 (ANI/BusinessWire India): IQVIA (NYSE: IQV) today announced that Dr. Reddy''s Laboratories (Dr Reddy''s), a leading multinational pharmaceutical company based in India, has selected IQVIA Orchestrated Customer Engagement (OCE) platform as its core CRM solution for its entire field force in India.
IQVIA Announces Partnership with Dr. Reddy’s Laboratories for CRM Solution for India Field Force 2022/09/28 03:30:00 businessfortnight.com
Mumbai, Maharashtra, Bangalore, Karnataka, India: IQVIA (NYSE: IQV) as we speak introduced that Dr. Reddy’s Laboratories (Dr. Reddy’s), a number one multinational pharmaceutical firm based […] The post IQVIA Announces Partnership with Dr. Reddy’s Laboratories for CRM Solution for India Field Force appeared first on Businessfortnight .
IQVIA Holdings – Consensus Indicates Potential 25.7% Upside 2022/09/15 12:14:54 DirectorsTalk
IQVIA Holdings with ticker code (IQV) now have 19 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 300 and 235 with a mean TP of 267.16. With the stocks previous close at 212.51 this would indicate that there is a potential upside of 25.7%. The 50 day moving average now sits at 225.76 and the 200 day MA is 231.99. The company has a market capitalisation of $39,004m. Company Website: https://www.iqvia.com [stock_market_widget type="chart" template="basic" color="green" assets="IQV" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $49,035m based on the market concensus. IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
IQVIA Holdings – Consensus Indicates Potential 27.9% Upside 2022/09/08 10:48:00 DirectorsTalk
IQVIA Holdings with ticker code (IQV) have now 19 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 300 and 235 with the average target price sitting at 268.21. Given that the stocks previous close was at 209.66 this now indicates there is a potential upside of 27.9%. There is a 50 day moving average of 225.28 and the 200 day MA is 233.16. The market capitalisation for the company is $40,125m. Visit the company website at: https://www.iqvia.com [stock_market_widget type="chart" template="basic" color="green" assets="IQV" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $51,331m based on the market concensus. IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
IQVIA Holdings – Consensus Indicates Potential 20.2% Upside 2022/07/28 12:10:51 DirectorsTalk
IQVIA Holdings found using ticker (IQV) have now 18 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 290 and 235 with a mean TP of 264. With the stocks previous close at 219.68 this is indicating there is a potential upside of 20.2%. The day 50 moving average is 212.3 and the 200 day moving average is 236.18. The market capitalisation for the company is $41,989m. You can visit the company''s website by visiting: https://www.iqvia.com [stock_market_widget type="chart" template="basic" color="green" assets="IQV" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $50,460m based on the market concensus. IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
New Insight On IQVIA Holdings Inc. (IQV) 2022/07/23 13:30:00 Stocks Register
IQVIA Holdings Inc. (NYSE:IQV) concluded the trading at $221.74 on Friday, July 22 with a fall of -1.72% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $225.63 and 5Y monthly beta was reading 1.46 with its price kept floating in the … New Insight On IQVIA Holdings Inc. (IQV) Read More »
S&P 500 Analyst Moves: IQV 2022/07/22 16:25:16 Nasdaq
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, IQVIA Holdings is now the #22 analyst pick, moving up by 1 spot.
IQVIA Holdings Inc. (IQV) Q2 2022 Earnings Call Transcript | AlphaStreet 2022/07/22 12:30:05 AlphaStreet
IQVIA Holdings Inc. (NYSE: IQV) Q2 2022 earnings call dated Jul. 21, 2022
IQVIA Holdings PT Raised to $261 at Jefferies 2022/07/22 12:09:01 Investing.com
https://www.investing.com/news/pro/iqvia-holdings-pt-raised-to-261-at-jefferies-432SI-2851905
IQVIA Holdings – Consensus Indicates Potential 17.1% Upside 2022/04/07 11:45:25 DirectorsTalk
IQVIA Holdings found using ticker (IQV) have now 17 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 300 and 231 and has a mean target at 279.12. With the stocks previous close at 238.36 this is indicating there is a potential upside of 17.1%. There is a 50 day moving average of 231.83 and the 200 moving average now moves to 249.3. The market capitalisation for the company is $45,877m. Find out more information at: https://www.iqvia.com [stock_market_widget type="chart" template="basic" color="green" assets="IQV" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $53,722m based on the market concensus. IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
IQVIA Holdings – Consensus Indicates Potential 19.5% Upside 2022/03/31 12:09:33 DirectorsTalk
IQVIA Holdings with ticker code (IQV) have now 17 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 300 and 231 with the average target price sitting at 279.12. Now with the previous closing price of 233.59 this would imply there is a potential upside of 19.5%. The 50 day moving average now sits at 232.39 and the 200 day MA is 249.53. The company has a market capitalisation of $44,162m. Find out more information at: https://www.iqvia.com [stock_market_widget type="chart" template="basic" color="green" assets="IQV" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $52,770m based on the market concensus. IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS) 2022/03/14 13:00:00 Kwhen Finance
Grosvenor Holdings, L.L.C. Buys Rivian Automotive Inc, Carvana Co, Expedia Group Inc, Sells ... 2022/02/18 23:38:37 GuruFocus
Related Stocks: CVNA , ROAD , RIVN , EXPE , TXRH , PCG , IQV ,
IQVIA Holdings – Consensus Indicates Potential 26.8% Upside 2022/02/17 11:52:32 DirectorsTalk
IQVIA Holdings with ticker code (IQV) have now 17 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 325 and 255 with the average target price sitting at 289.94. Given that the stocks previous close was at 228.64 this is indicating there is a potential upside of 26.8%. The day 50 moving average is 257.76 and the 200 moving average now moves to 251.16. The company has a market capitalisation of $44,356m. Company Website: https://www.iqvia.com [stock_market_widget type="chart" symbol="IQV" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $56,248m based on the market concensus. IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.